The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
Abstract Background Systemic treatment of advanced non-small cell lung cancer (NSCLC) has changed dramatically since the introduction of targeted therapies. The analysis of circulating tumor DNA (ctDNA) is a valuable approach to monitor the clonal evolution of tumors during treatment with EGFR-tyros...
Main Authors: | Marzia Del Re, Eleonora Rofi, Carla Cappelli, Gianfranco Puppo, Stefania Crucitta, Simona Valeggi, Antonio Chella, Romano Danesi, Iacopo Petrini |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-04-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-019-5604-6 |
Similar Items
-
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01) -
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
by: Wang J, et al.
Published: (2016-06-01) -
Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
by: Zhonghan Zhang, et al.
Published: (2020-06-01) -
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
by: Wang X, et al.
Published: (2016-09-01) -
ΔCT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non–Small-Cell Lung Cancer: A Multi-Center Retrospective Study
by: Min Chen, et al.
Published: (2021-10-01)